TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Naturally or surgically menopausal~* Minimum 7 daily or 50 weekly moderate-to-severe hot flashes~Exclusion Criteria:~* Any contraindication to hormone therapy

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 0.3 mg SCE-B Daily
- 2 (Type: EXPERIMENTAL): 0.625 mg SCE-B Daily
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult male or female volunteers~* Japanese~* Subjects aged between 20 and 45 years at the time of informed consent~* Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study~Exclusion Criteria: Additional screening criteria check may apply for qualification:~* Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study~* Body mass index (BMI) of \<18.0 or \>30.0, or body weight of \<50 kg (BMI formula: body weight \[kg\]/height \[m\]2, rounded to one decimal place)~* Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs~* Female subjects who do not agree to use an effective method of contraception from screening or 2 weeks before the start of investigational product administration, whichever comes earlier, to 14 days after the completion (or discontinuation) of investigational product administration. Male subjects who do not agree to use an effective method of contraception from the start of investigational product administration to 14 days after the completion (or discontinuation) of investigational product administration~* Subjects who have previously received edaravone~* Subjects who have participated in another clinical study and received an investigational product within 12 weeks before providing informed consent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- MT-1186 (Type: EXPERIMENTAL): Healthy subjects were administered a single dose of Edaravone oral suspension
- MCI-186 (Type: ACTIVE_COMPARATOR): Healthy subjects were administered a single dose of Edaravone intravenous formulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Receipt of ADACEL vaccine during the study period~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males, 20 to 45 years of age the moment of screening~* Body mass index is between 18.0 and 30.0 kg/m~Exclusion Criteria:~* The tuberculosis patient of latent tuberculosis patient~* Hypersensitivity response to the test and comparator drugs

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Enbrel, LBEC0101
- Group 2 (Type: EXPERIMENTAL): LBEC0101, Enbrel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and non-pregnant females at least 6 years of age~* History of recurrent unilateral or asymmetric non-infectious posterior uveitis of at east 1 year duration not associated with significant systemic activity of the disease~* The more severely affected eye having had at least 2 separate recurrences~* The more severely affected eye having been treated by systemic therapy for at least one month just before inclusion~* Visual acuity (VA) of at least 1.4 logMAR units at enrollment~* At time of enrollment, \</=10 anterior chamber cells/HPF and vitrous haze\</= grade 2.~Exclusion Criteria:~* known allergy or contraindication to fluocinolone acetonide, systemic corticosteroids, or the immunosuppressive agents to be administered~* history of retinal detachment, retinoschisis in the area of implantation, or media opacity precluding evaluation of the retina and vitreous~* presence or history of uncontrolled IOP while on steroid therapy resulting in loss of vision, or IOP \>25 mm Hg requiring at least 2 types of antiglaucoma medication to be reduced to \<25 mm Hg~* history of NIPU only or iritis only with no vitritis, macular edema, vitreous cells, or vitreous haze~* infectious etiology, vitreous hemorrhage, or a toxoplasma scar in the study eye~* ocular surgery and/or trauma on the study eye within 3 months prior to enrollment, or trabeculoplasty or yttrium aluminum garnet laser within 1 month prior to study enrollment~* monocularity~* AIDS~* pregnancy/lactation~* potential for noncompliance~* or participation in other clinical studies within 1 month of enrollment.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluocinolone acetonide (Type: EXPERIMENTAL): Intravitreal fluocinolone acetonide implant
- Standard care (Type: ACTIVE_COMPARATOR): Standard of Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Ultrasound-guided Hydrodilatation With Hyaluronic Acid for Patients With Adhesive Capsulitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. a duration of complaints more than 3 months~2. a reduction in passive range of motion in at least 2 of the following: forward flexion, abduction, or external rotation of the affected shoulder of more than 30 degree compared with the other side.~Exclusion Criteria:~1. prior manipulation of the affected shoulder under anesthesia;~2. other conditions involving the shoulder ( rheumatoid arthritis, Hill-Sachs lesions, osteoarthritis, damage to the glenohumeral cartilage,osteoporosis, or malignancies in the shoulder region);~3. neurologic deficits affecting shoulder function in normal daily activities;~4. shoulder pain caused by cervical radiculopathy~5. a history of drug allergy to hyaluronic acid;~6. pregnancy or lactation;~7. received injection into the affected shoulder during the preceding 3 months

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- physical therapy and hyaluronic acid (Type: EXPERIMENTAL): patient received ultrasound-guided hydrodilatation with hyaluronic acid plus physical therapy
- physical therapy only (Type: ACTIVE_COMPARATOR): patient received physical therapy only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* baseline gravimetric measurement of spontaneous resting sweat production of at least 50 mg/5 min at room temperature in each axilla~* poor quality-of-life rating on the Hyperhidrosis Disease Severity Scale~* primary focal axillary hyperhidrosis evidenced by at least two of the standard criteria~* female subjects of child-bearing potential must not be pregnant or lactating and must agree to not become pregnant during the course of the study including follow-up period~* female subjects over 40 must have had a mammogram in the last 2 years~* subjects must be willing to comply with study visits and requirements~Exclusion Criteria:~* subject has secondary hyperhidrosis (e.g., endocrinopathy, medications)~* subject has active infection~* subject is pregnant or lactating~* subject has had prior surgery for axillary hyperhidrosis~* subject has had axillary injections of botulinum toxin A in the last year~* subject has used prescription antiperspirants in the last 14 days or plans to use them during the study period~* subject has used oral anticholinergics in the last 4 weeks~* subject is a prisoner or under incarceration~* subject is participating in a another clinical trial (or has in the last 30 days)~* subject has history of cancer (some exceptions)~* subject has a pacemaker or other electronic implant~* subject requires supplemental oxygen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with DTS-G2 System (Type: EXPERIMENTAL): Subjects receive treatment with the DTS-G2 System (an energy-based medical device) in both axilla. Multiple treatment sessions may be used.
- Sham treatment (Type: SHAM_COMPARATOR): All elements of the treatment are given except that no energy is delivered. Multiple treatment sessions may be used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Photobiomodulation and Manual Therapy Alone or Combined in TMD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* TMD myogenic and arthrogenic diagnosis based in RDC/TMD Axis I analysis~* Pain in temporomandibular joint (TMJ)~* Limitation in mouth opening.~Exclusion Criteria:~* Current dental or physical treatment~* Polyarthritis and other rheumatic diseases~* Use of anti-inflammatory and muscle relaxant

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Photobiomodulation group (PBM) (Type: EXPERIMENTAL): Gallium-aluminium-arsenide (GaAlAs) diode laser (MM Optics Recover, São Carlos, São Paulo, Brazil) with a wavelength of 808 nm, punctual contact mode,spot size of 0.03 cm2, power output of 100 mW, output density of 333 mW∕cm2, energy density of 13.3 J ∕cm2, 40 s exposure time per point, and 4 Joules (J) of total energy per point.~18 individuals
- Manual Therapy group (MT) (Type: EXPERIMENTAL): At masticatory muscles were performed circular movements, slip and compression with fingers movements. At the temporomandibular joint (TMJ) was performed a caudal distraction with anterior projection, placing the thumb on the second or third molar.~16 individuals.
- Combined therapy group (CT) (Type: EXPERIMENTAL): Applied the protocols of PBM group and immediately after, to MT group. 17 individuals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of SEvoflurane on Gas Exchange and Inflammation in Patients With ARDS (SEGA Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with criteria for moderate to severe ARDS since less than 24 hours (~* Informed consent~Exclusion Criteria:~* Suspected or proven intracranial hypertension~* Midazolam, sevoflurane or cisatracurium allergy~* Medical history of malignant hyperthermia~* Severe liver failure~* Chemotherapy treatment in the last month~* Severe neutropenia (\< 0.5 G/l)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- conventional group (Type: EXPERIMENTAL): a conventional group, in which intravenous sedation with midazolam will be administered
- sevoflurane group (Type: EXPERIMENTAL): a sevoflurane group, in which patients will inhale sevoflurane during a 48 hour-period, through dedicated devices

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Application of Platelet Function Test in Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 - 80, male or non-pregnant female;~2. patients have unruptured aneurysm who plan to undergo intracranial stent placement;~3. patients with less than 2 of modified Rankin scale score at the day of enrollment;~4. patients who is able to understand the objective of the trial, agrees and signs the written informed consent form.~Exclusion Criteria:~1. The complications related to operation or material quality, such as guidewire pierces out blood vessel, coil herniation, incompletely opened stent, etc;~2. Simultaneous treatment of other cerebrovascular diseases, such as intracranial arteriovenous malformation, Intracranial arteriovenous fistula, etc;~3. Patient with history of hypersensitivity of aspirin, clopidogrel, or ticagrelor;~4. Patients with preoperative prophylactic use of tirofiban;~5. Patients with a high possibility of active bleeding, such as symptomatic intracranial hemorrhage or active gastric ulcer; or patients with coagulopathy;~6. Patients with thrombocytopenia (platelet count \<100,000/mm3 within three months before enrollment);~7. patient using anticoagulant;~8. Pregnant or lactating women;~9. Patients with malignant diseases, such as liver disease, kidney disease, congestive heart failure, malignant tumors, etc;~10. Poor compliance patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Monitoring Arm (Type: EXPERIMENTAL): Randomization: based on light transmittance aggregometry, modified dose of antiplatelet therapy(aspirin and ticagrelor) was used for high platelet reactivity(HPR) patients with intracranial stent placement, and standard antiplatelet regimen(aspirin and clopidogrel) was used in non-HPR patients.
- Conventional Arm (Type: EXPERIMENTAL): Randomization: without light transmittance aggregometry, standard antiplatelet regimen was used for unruptured aneurysm patients with intracranial stent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be HIV positive with HIV RNA values that are within ranges required by the study~* Patient must have documented failure of certain antiretroviral therapy~* Patient must be on the same antiretroviral therapy for at least the past two months~Exclusion Criteria:~* Patient less than 16 years old~* Additional study criteria will be discussed and identified by the study doctor

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): raltegravir potassium
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Using an Oil Bath Additive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent, or children whose parent(s) or guardian(s) have given their written informed consent for their child's participation in the study~* Child specific written informed consent, if over 7 years of age~* Subjects with a general good and stable health condition~* Subjects with clinically stable medical conditions~* Accept to abstain from sunbathing and solarium during the study~* Overall Dry Skin score (ODS) of 1 to 2 at arms and lower legs~* TEWL \> 12 g/m2/h on the left mid volar forearm~Exclusion Criteria:~* Any dermatological condition or skin affection which may interfere with the study assessments, e.g. scars~* Suffering from porphyria~* Suffering from severe photodermatoses according to the judgment of the investigator~* Clinically significant, possibly unstable medical conditions such as metastatic tumor~* Currently having other malignant or benign tumors of the skin in the investigational area~* Any other acute or chronic pathology that may interfere with the study conduct in the investigator's opinion~* Known allergy or intolerance to any ingredients of the study product, e.g. propylene glycol~* Use of (medical) oil-containing bath additives or other oil-containing cleansers~* Current topical or systemic treatment affecting the skin, e.g. diuretics~* Treatment of dry and/or inflammatory skin conditions with topical corticosteroids during the 4 weeks before inclusion~* Systemic immunosuppressive or immunomodulatory therapy~* Topical retinoids applied during the 6 weeks before inclusion~* Topical application of immunosuppressive treatment during the 6 weeks before inclusion~* Therapeutic UV-Radiation during the 6 weeks before inclusion~* Increased UV-exposure during the 6 weeks before inclusion

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Balneum oil bath (Type: EXPERIMENTAL): Balneum oil bath, bathing every other day for four weeks
- standard skin cleanser (Type: NO_INTERVENTION): Usual skin cleanser (non-oil containing), bathing or showering every other day for four weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults~* Male and female~* Between ages 18 and 90~* Undergo a Polysomnography (PSG) with evidence of any sleep disordered breathing including snoring, mild/moderate/severe sleep apnea, and/or restless legs~Exclusion Criteria:~* Ages 17 and under~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 14 days of Placebo therapy, then CPAP (Type: PLACEBO_COMPARATOR): 14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
- 14 days of CPAP therapy (Type: ACTIVE_COMPARATOR): 14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Histologically/cytologically confirmed hepatocellular carcinoma not amenable to curative surgery or loco-regional therapy~2. Age 20 years or older~3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1~4. Child-Pugh score of 7 or less~5. Life expectancy more than 3 months~6. Time interval from last loco-regional therapy more than 4 weeks~7. Written informed consent in accordance with good clinical practice (GCP)~Exclusion criteria:~1. More than one line of prior systemic therapy for metastatic/unresectable hepatocellular carcinoma (HCC)~2. Fibrolamellar HCC~3. Uncontrolled or refractory ascites~4. Inadequate organ function~5. Variceal bleeding within 6 months or the presence of inappropriate varices~6. History of major thrombotic (except portal vein thrombosis) or clinically relevant major bleeding event in the past 6 months~7. Major surgery within 4 weeks~8. Known inherited predisposition to bleeding or thrombosis~9. Significant cardiovascular diseases

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): patients with mild liver dysfunction according to their AST/ALT values and Child-Pugh score
- Group II (Type: EXPERIMENTAL): patients with moderate liver dysfunction according to their AST/ALT values and Child-Pugh score

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete